Effect of allerglobuline injection on serum immunoglobulin levels in ENT patients

Allerglobuline is a human gammaglobulin preparation which has been reported to have a protective effect against Type I allergic diseases and chronic infection of the upper respiratory tract both in adults and children. This study included 64 patients suffering from perennial allergic rhinitis and/or chronic infection of the nose, paranasal sinuses and pharynx. All patients received Allerglobuline 10 ml intramuscular injection once a week for 5 times then once a month for another 3 times. Blood samples were taken before the first and after the last injections to assay for the levels of Igs G, A, M and E. The therapeutic responses were evaluated after the fifth injections by dividing into 5 grades (from Grade I = excellent to Grade V = no response). Statistical analysis revealed that there was no significant difference between the pre- and post-treatment levels of Igs, G, A and M. But the level of IgE decreased significantly after 8 injections (p less than 0.001). There was no correlation between the level of immunoglobulins and grade of therapeutic responses. But the number of patients who respond satisfactorily to Allerglobuline treatment increased from 62.26% after 5 injections to 77.36% after 8 injections. This difference does not reach the statistically significant level but is noteworthy.